Peptides and Proteins as Drugs
- 1 January 1985
- journal article
- review article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 02 (4) , 151-156
- https://doi.org/10.1023/A:1016327803573
Abstract
Relatively small modifications of clinically useful endogenous compounds have been shown to have therapeutically beneficial effects on their pharmacodynamic and pharmacokinetic properties. These effects include increased potency and effect selectivity, and prolonged duration of action. In addition, these modifications have resulted in compounds that can be administered orally where only parenteral administration was previously possible. One type of modification resulting in distinctive properties is exemplified by the hybrid interferons produced by the recombination of segments of genes coding for different molecular species. Chemical modification has also resulted in many examples of analogs of natural peptides that are more potent, more selective and more stable than the endogenous compounds. Conjugation to peptide or protein carriers is a third method used to selectively modify the properties of an endogenous compound. The carriers that have been used include synthetic polypeptides, endogenous proteins, toxins and monoclonal antibodies. The effect that covalent attachment to a carrier has on the properties of a ligand is highly dependent upon the carrier, the ligand and the linkage between them.Keywords
This publication has 57 references indexed in Scilit:
- Killing of human tumor cells in culture with adriamycin conjugates of human transferrinClinical Immunology and Immunopathology, 1984
- New Compounds: Peptide Derivatives of the Antitumor Agent N-Phosphonoacetyl-L-aspartic AcidJournal of Pharmaceutical Sciences, 1984
- Preparation and properties of a drug‐carrier‐antibody conjugate showing selective antibody‐directed cytotoxicity in vitroInternational Journal of Cancer, 1983
- Conjugates of catecholamines. 1. N-Alkyl-functionalized carboxylic acid congeners and amides related to isoproterenolJournal of Medicinal Chemistry, 1983
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- Synthesis of human corticotropinyl‐thiolglycine and its specific conjugation to bovine serum albuminInternational Journal of Peptide and Protein Research, 1982
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982
- Epidermal growth factor-toxin A chain conjugates: EGF-Ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxicCell, 1980
- Synthesis of a cytotoxic insulin cross-linked to diphtheria toxin fragment a capable of recognizing insulin receptorsBiochemical and Biophysical Research Communications, 1979
- Preparation of a hybrid of fragment Fab' of antibody and fragment a of diphtheria toxin and its cytotoxicityBiochemical and Biophysical Research Communications, 1979